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Abstract
Introduction TL1A (TNFSF15) augments IFN-γ production
by IL-12/IL-18 responsive human T cells. Its ligand, death
domain receptor 3 (DR3), is induced by activation on Tand NK
cells. Although IL-12/IL-18 induces DR3 expression on most
NK cells, addition of TL1A minimally increases IFN-γ
production.
Methods
51Chromium release and flow cytometric analysis
were used to determine whether the TL1A-DR3 pathway is
implicatedintumorcelllysis.Ouraimwastodeterminewhether
the TL1A-DR3 pathway is implicated in tumor cell lysis.
Results TL1A had no additional effect on IL-12/IL-18-
induced cytotoxicity against an NK-susceptible tumor
(K562); however, it promoted cytotoxicity against NK-
resistanttargetssusceptibletolysisonlybyactivatedNKcells.
Discussion With IL-12/IL-18 activation, TL1A increased
CD107a expression on NK cells which led to enhanced
lysis of Daudi by PBMC and purified NK cells. To a
lesser degree, TL1A increased lysis of colorectal adeno-
carcinoma epithelial derived lines (WiDr and SW837) by
IL-12/IL-18-activated cells.
Conclusion TL1A increased cytotoxicity of IL-12/IL-18-
activated NK cells against target cells dependent on NK
activation for lysis and could function in vivo as a key co-
activator of NK cytotoxicity.
Keywords Natural killer cells.cytotoxicity.cytokines.
tumor immunity
Introduction
Natural killer cells (CD56
+,C D 3
−) play an important role in
innate immune defense by eliminating pathogen-infected and
tumor cells through cytokine production and cytotoxicity.
NK cell effector function is the result of an integration of
signals from MHC class I-specific inhibitory receptors and
several types of activating receptors, including a variety of
co-stimulatory and adhesion molecules [11, 18, 32]. Cyto-
toxicity of NK cells is mediated through the Ca
2+-dependent
granule exocytosis pathway involving perforin/granzyme
release and target lysis or through a Ca
2+-independent
mechanism involving Fas/CD95L-mediated apoptosis. A
role for TNF Related Aptosis Inducing Ligand (TRAIL)
and other TNF-family ligands in apoptosis of tumor targets
by NK cells has been described [13, 29].
IL-12 stimulates NK cells, inducing IFN-γ production
[5, 14] enhancing cytolytic activity [6] and stimulating
proliferation [12]. IL-18 also enhances NK lytic activity,
and IL-18-deficient mice show impaired NK cell activity, as
do IL-12-deficient mice. In mice lacking both cytokines, NK
lytic activity is further impaired, indicative of IL-12 and IL-18
s y n e r g yi nv i v o[ 28]. NK cells, unlike T cells, constitutively
express high-affinity receptors for both cytokines.
We reported that the TNF superfamily member TL1A
synergized with IL-12/IL-18 to augment IFN-γ production
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DOI 10.1007/s10875-010-9382-9in resting human PB T and NK cells [23]. Since its
identification, TL1A has been suggested to play a role in
several inflammatory diseases. A partial, and in some cases
substantial, inhibition of disease symptoms in mouse
models of colitis, asthma, arthritis, and experimental
autoimmune encephalitis is seen in mice in which TL1A
is either attenuated with an antibody or knocked out. This
attenuation of disease is also seen in disease models where
the TL1A receptor, DR3 (TNFSFR25), is knocked out [4,
9, 19, 25].
DR3 is not expressed on unstimulated Tand NK cells, but
it is induced on a small subset of Tcells and on up to 70% of
NK cellsby IL-12and IL-18. However,while engagementof
DR3 by TL1A augments IL-12/IL-18-induced IFN-γ pro-
duction 3–15-fold in T-cell cultures, the increase in NK cell
cultures is a modest 2-fold and is due solely to stimulation of
NK proliferation, not to increased IFN-γ production per cell.
Given the induction of DR3 on most NK cells by IL-12/IL-
18, we, therefore, investigated whether TL1A also regulates
another function of cytokine-activated NK cells, cytotoxicity
against tumor cells.
In the present study, we show that TL1A, while not
affecting lysis of NK-sensitive K562 cells, augments IL-12/
IL-18-induced NK cell cytotoxicity against NK-resistant
Daudi cells independent of the possible effects of induced
IFN-γ and to a lesser degree the lysis of the colorectal
adenocarcinoma epithelial derived cell lines WiDr and
SW837. Thus, TL1A can augment the cytotoxicity of IL-
12/IL-18-activated NK cells against transformed cell targets
susceptible to lysis only by activated NK cells. These
results suggest that TL1A could play an important
amplifying role in NK surveillance of certain tumors based
on NK resistance.
Methods
Cytokines and Antibodies
Recombinant TL1A (aa 72–251) and anti-DR3 antibody
(clone 01F05) were generated and tested for specificity at
Teva Pharmaceuticals. Recombinant IL-12 (Peprotech,
Rocky Hill, NJ) was used at 40 pg/ml except for the initial
experiment (Fig. 1a) where it was used at 1 ng/ml for
PBMC and 0.4 ng/ml for NK cells. IL-18 (R&D Systems,
Minneapolis, MN) was used at 54 ng/ml in all experiments.
The cytokines tested for the induction of DR3 expression
on NK cells were used at concentrations as follows:
recombinant IFN-α, IFN-β, IFN-γ, and IL-2 (Peprotech),
200 U/ml; recombinant IL-15 and TNF-α (R&D Systems),
50 and 10 ng/ml, respectively; and Phorbol 12-myristate
13-acetate (PMA) and ionomycin (Sigma-Aldrich Inc., St.
Louis, MO), 10 and 0.2 μg/ml, respectively. Isotype- or
species-specific control antibodies were from Jackson
ImmunoResearch (West Grove, PA), anti-CD3 and-CD56
fluorochrome-conjugated mAbs were from Caltag (South
San Francisco, CA), and anti-CD107a was from eBio-
science (San Diego, CA).
PBMC Isolation and Culture
Blood was obtained from normal donors in accordance with
the Human Subjects policy of the Cedars-Sinai Medical
Center Institutional Review Board. PBMC were isolated on
standard Ficoll–Hypaque density gradients and depleted of
monocytes by adherence for 2 h. NK cells isolated from
PBMC by negative selection (NK cell isolation kit,
Miltenyi Biotec, Auburn, CA), and thus not exposed to
potentially stimulatory mAb, yielded a population greater
than 95% CD56+, CD3− NK cells. For some experiments,
the cells retained in the column were eluted and tested as
the non-NK fraction. PBMC, purified NK cells, and the
non-NK fraction were cultured at 0.5×10
6 cells/ml in RPMI
1,640 containing 2 mM glutamine and 25 mM HEPES
buffer (Mediatech Inc., Herndon, VA), supplemented with
10% fetal bovine serum (Atlanta Biologicals, Norcross,
GA, heat inactivated) and gentamycin (50 μg/ml, Omega
Scientific, Tarzana, CA) under conditions stated in the
figures. Supernatants were frozen for IFN-γ analysis by
ELISA.
Tumor Cell Lines
The cell lines K562 (chronic myelogenous leukemia,
ATCC CCL 243), Daudi (Burkitt’s lymphoma, ATCC
CCL 213), and SW837 (rectal adenocarcinoma, ATCC
CCL 235) were all grown in RPMI 1,640 supplemented
as indicated above. WiDr cells (colorectal adenocarci-
noma, ATCC CCL 218) were cultured in Minimum
Essential Medium Eagle with Earle’ss a l t sa n dl-
glutamine (Mediatech, Inc., Herndon, VA), with 10% fetal
bovine serum and gentamycin. The leukemic suspension
cell lines were used in the log phase of growth and the
adherent epithelial cell lines when reaching 70% conflu-
ency, harvested by using Trypsin EDTA (0.25% Trypsin
and 1 mM EDTA-4Na, Gibco Invitrogen Corp., Grand
Island, NY) according to ATCC protocols.
Cell Staining for Flow Cytometry
To study surface DR3 expression on NK cells, PBMC were
blocked with goat IgG for 20 min on ice and incubated with
anti-DR3-specific monoclonal or isotype control antibody
on ice. The cells were then washed with PBS/0.5% BSA
and incubated with anti-mouse secondary antibody conju-
gated to phycoerythrin (Caltag, Burlingame, CA) for
532 J Clin Immunol (2010) 30:531–53830 min on ice. After washing with PBS/BSA and blocking
with mouse IgG for 20 min, cells were stained with CD3-
FITC and CD56-tricolor (TC) for 20 min on ice and
analyzed by flow cytometry (Becton Dickinson, Mountain
View, CA). DR3 expression was analyzed on NK cells by
gating on lymphocytes based on forward and side scatter
and further gating on CD3− CD56+ cells; 5×10
4 cells were
acquired and both the percentage of NK cells expressing
DR3 and the mean fluorescence intensity of DR3+ cells
were obtained. Percentage nonspecific staining by isotype
control Ab or percentage specific staining of the control
condition, respectively, was subtracted from percentage-
specific staining of the test condition, as indicated in the
figure legends.
Detection of IFN-γ by ELISA
IFN-γ in culture supernatants was detected by amplified
sandwich ELISA and quantitated as previously reported
[31].
Cytotoxicity Assay
Cytolytic activity was determined by 2 to 3-h
51Cr-release
assays [10]. K562, Daudi, SW837, and WiDr were used as
target cells. NK cells, non-NK cells, and PBMC were used
as effector cells. Target cell pellets (3×10
6 cells) were
labeled with 150 μCi of Na2
51CrO4 (Perkin Elmer, Boston,
MA) at 37°C for 1 h. The target cells were washed twice
with Hanks’ Buffered Salt Solution (Mediatech Inc.,
Herndon, VA) and 10
4 cells/well were incubated in 200 μl
RPMI 1,640 medium (specified above) with effector cells at
six different effector/target (E/T) ratios, ranging from 14:1
to 100:1 for PBMC and the non-NK cell fraction and 1.4:1
to 10:1 for purified NK cells. Wells containing target cells
alone were used to determine spontaneous release, and 10%
Triton X-100 was added to determine maximum target
51Cr
release. Assay plates were centrifuged briefly and incubated
at 37°C for 2 to 3 h.
51Cr released into supernatants by
lysed target cells was measured in a gamma counter and
mean cpm calculated. The data are presented as lytic units
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Fig. 1 TL1A synergizes with
IL-12 and IL-18 to increase
IFN-γ production in PBMC and
NK cells but does not enhance
cytolytic activity of PBMC and
NK cells against the NK-
sensitive K562 cell line. a
PBMC and purified NK cells
were cultured with medium
(Control) or a maximal concen-
tration of IL-12 and IL-18 with-
out or with TL1A (50 ng/ml),
and their cytotoxicity was tested
against the NK-sensitive cell
line K562 in
51Cr-release assays
and expressed in lytic units
(LU30, left panels). Culture
supernatants were collected at
72 h and analyzed for IFN-γ
content by ELISA (right pan-
els). Results are representative
of two experiments with similar
results. b PBMC and purified
NK cells of the same donor were
cultured as in 1A but with a
lower IL-12 concentration
(40 pg/ml). Results are repre-
sentative of three experiments
for PBMC, two experiments for
NK cells. TL1A-treated PBMC
produced significantly more
IFN-γ (p=0.05) while no sig-
nificant difference was seen in
cytotoxicity. LU30, the number
of effector cells required to lyse
30% of a standard number of
target cells, here 10
4 target cells.
Bars SD
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7 effectors. Percent specific lysis and lytic units
were calculated using a computer program developed by R.
Deem. The following formula was used to calculate the
percent specific lysis:
PSL ¼ ER   SR ðÞ = MR   SR ðÞ ½    100
where ER denotes the experimental release, SR is the
spontaneous release, and MR is the maximal release. Lytic
units were calculated as:
LU30=107 cells ¼ ESTD= E=T30 ðÞ   TSTD ðÞ
in which ESTD is 10
7 effector cells, E/T30 is the E/T ratio at
which 30% of the target cells are killed and TSTD is 10
4
target cells. For flow cytometric cytotoxicity, the same
protocol was followed, substituting target cells labeled with
5- (and 6)-carboxyfluorescein diacetate succinimidyl ester
(CFSE, 1 μM, eBioscience) for 10 min at room temperature
per manufacturer’s instructions in place of those labeled by
51Cr. IFN-γ blocking antibody (clone NIB42, BD Bio-
sciences, San Jose, CA) or isotype specific control antibody
(eBioscience, San Diego) was added at 5 μg/ml. At the end
of the 2 h assay, three to four wells for each E/T ratio were
combined and stained with anti-CD107a and 7-amino-
actinomycin D (7-AAD, eBioscience, 1.25 μg/ml). Targets
were gated by size (forward angle light scatter (FSC)) and
CFSE with cytotoxicity assessed as the % 7-AAD
+/CFSE
+.
Lytic units were calculated using a linear regression of the
individual cytotoxicity measurements. NK expression of
CD107a was based on CFSE
− cells gated by FSC.
Statistical Analysis
The paired t test was performed using JMP IN 5.1 data
analysis software to determine the significance of the
difference in cytotoxicity of IL-12/IL-18-treated PBMC
without and with TL1A.
Table 1 Other Known NK Cell Activating Stimuli Do Not Upregulate
DR3 Expression
Culture condition % DR3-positive NK cells
Control 5.3
IFN-γ 3.9
IFN-β 5.4
IFN-αIFN-β 8.9
IFN-αIFN-βIL-12 6.2
PMA+Ionomycin 1.3
IL-15 7.5
IL-2 7.3
IL-2+IL-15 1.9
IL-2+IL-12 0.6
IFN-γ 8.6
TNF-α 5.0
IL-12 (1 ng/ml)+IL-18 64.6
IL-12 (40 pg/ml)+IL-18 40.0
PBMC were incubated with medium (Control) or with cytokines alone
or in combination as indicated for 48 h or with PMA + Ionomycin for
18 h, stained indirectly for DR3 (“Methods”), and analyzed by flow
cytometry
Percentage of DR3-specific staining in the NK cell population in one
representative experiment of two with similar results
Control
IL-12 + IL-18
IL-12 + IL-18 + TL1A
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Fig. 2 TL1A enhances NK cell cytotoxicity against NK-resistant cell
lines, particularly against Daudi cells. PBMC were cultured and then
tested for cytotoxicity to the NK-resistant target cells Daudi (n=7),
WiDr (n=3), and SW837 (n=3) in
51Cr-release assays (lower three
panels) and compared to the cytotoxicity toward K562 cells (n=3,
upper panel). TL1A-treated PBMC were significantly more cytotoxic
to Daudi cells than that induced by PBMC and IL-12/IL-18 alone
(*p<0.0004 at 72 h and **p<0.009 at 96 h). Mean values and SEM
are shown
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DR3 is Induced on NK Cells by IL-12/IL-18,
but not by Other NK-stimulating Cytokines
DR3 is the receptor for TL1A, the only DR3-ligand of
several tested by Migone et al. [20]. In a previous study, we
showed that DR3 expression could be induced on up to
70% of NK cells by maximally effective concentrations of
the combined cytokines IL-12 and IL-18 [23]. Other
cytokines known to activate NK cells might also induce
DR3 expression, but only IL-12/IL-18, of a panel of
cytokines and cytokine combinations that we tested were
capable of significant induction of DR3 (Table 1).
TL1A Does Not Enhance Cytotoxicity
against NK-Sensitive K562 Target Cells
We demonstrated previously that TL1A augments IL-12/IL-
18-induced IFN-γ production in NK cells by about 2-fold,
largely due to NK proliferation [23]. Given the dramatic
i n d u c t i o nb yI L - 1 2 / I L - 1 8o fD R 3o nN Kc e l l s ,w e
hypothesized that TL1A might affect another NK effector
function, cytotoxicity, as well as IFN-γ production.
While the TL1A/DR3 pathway was functional as
evidenced by enhanced IFN-γ production in response to
TL1A by cells cultured with IL-12 and IL-18 (Fig. 1a, right
panels: 2.1-fold increase in PBMC and 2.4-fold increase for
NK cells), there was no significant difference in cytolytic
activity with TL1A at supra-maximal IL-12/IL-18 concen-
trations (Fig. 1a, left panels). These concentrations, while
strongly inducing DR3, might maximize NK cell cytotox-
icity (Fig. 1a, left panels) and thus obscure an effect of
TL1A on NK cell cytotoxicity. Therefore, we sought to
determine whether a lower concentration of IL-12 (with
maintained IL-18) would effectively induce DR3 expres-
sion on NK and perhaps not maximally stimulate cytotox-
icity. Lowering IL-12 concentration to 40 pg/ml still
resulted in DR3 induction on 40% of NK cells (Table 1)
with no decrease in MFI (data not shown), so we tested this
concentration in cytotoxicity experiments (Fig. 1b, left
panels). Our results demonstrated that cytotoxicity was not
NK Cytotoxicity
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Fig. 3 TL1A enhancement of
IL-12/IL-18-induced cytotoxic-
ity to Daudi cells is mediated
mainly by NK cells. a, b Puri-
fied NK (a) and the non-NK
fraction (b) from the same donor
were cultured, and their cytolyt-
ic activity was tested against
Daudi in a
51Cr-release assay. c,
d IFN-γ production by purified
NK (c) and non-NK cells (d)
from four different donors was
measured with and without
TL1A. Mean values and SEM of
two experiments are shown for
the lytic activity. Individual do-
nor results for IFN-γ production
and the fold increase for each
donor are shown. The average
fold increase for the four donors
is displayed on the side of
each figure
J Clin Immunol (2010) 30:531–538 535decreased, and TL1A still did not significantly enhance IL-
12/IL-18-induced cytolytic activity of PBMC and NK cells.
Additionally, at this lower level of IL-12, the effect of
TL1A on IFN-γ production was unimpaired in isolated NK
cells or even enhanced in PBMC relative to control
(Fig. 1b, right panels).
This set of results led us to the notion that TL1A might
enhance NK cell-mediated tumor lysis over a more
prolonged time-course. We, therefore, examined the effect
of TL1A on NK cytotoxicity in the same conditions for 96,
120, and 144 h. No significant difference in NK cell
cytotoxicity against K562 targets was detected with and
without TL1A (Fig. 1 and data not shown).
TL1A Enhances NK Cell Cytotoxicity against Cell Lines,
In Particular Daudi, Which are Lysed only by Activated
NK Cells
Cells from the K562 cell line are the commonly used target
cell for
51Cr-release assays using freshly isolated, unstimu-
lated PBMC or NK cells, while Daudi cells, which are
resistant to lysis by fresh NK cells, are used for assays of
cytotoxicity mediated by activated NK cells [10]. We
investigated whether TL1A had an effect on NK cell lytic
activity against the NK-resistant target cell lines Daudi,
SW837, and WiDr (Fig. 2). For PBMC, TL1A had the most
profound effect against Daudi target cells, enhancing
cytotoxicity 2-fold at 96 h of incubation (second panel).
The effect of TL1A on IL-12/IL-18-induced cytotoxicity of
PBMC against the NK-resistant epithelial cell lines WiDr
and SW837 showed a similar but not statistically significant
trend (Fig. 2, third and fourth panel).
Because T lymphocytes present in PBMC are capable of
lysing Daudi target cells [8], we wanted to clarify whether
our results with PBMC resulted from NK or non-NK cell
cytotoxicity. Using magnetic cell separation, we tested the
lytic activity of purified NK cells, compared to the non-NK
cell fraction, on the Daudi, SW837, and WiDR cells
(Fig. 3a and b). While the non-NK population, which
included CD56+ T cells, displayed some IL12/IL18-
induced cytotoxicity against Daudi cells, which was
enhanced by TL1A (Fig. 3b), TL1A had the most
significant effect on the lytic activity of purified NK cells
(Fig. 3a) where it augmented cytotoxicity by 7-fold in
Daudi cells compared to a 1.8-fold increase in NK cell IFN-
γ production (Fig. 3c). Comparatively, TL1A enhanced NK
lytic activity on the SW837 and WiDR cell lines, but to a
lesser degree, perhaps due to a much larger induction of
cytotoxicity by IL12/IL18. In contrast, in non-NK cells
(Fig. 3b) consisting mostly of T cells, TL1A increased
cytotoxicity by only 2-fold over IL12/18 alone in the Daudi
cells, and little to no activity was detected in the SW837
and WiDR cells. IFN-γ production in the non-NK cell
population increased an average of 5.2-fold in the presence
of TL1A. Together, these results suggest that the enhancing
effect of TL1A on the cytotoxicity of PBMC against the
Daudi and likely the SW837 and WiDr cell lines are
mediated mainly by augmenting the cytotoxicity of IL-12/
IL-18-activated NK cells.
TL1A-Enhanced Cytolytic Activity is Not Due to IFN-γ
Production
Given that TL1A induces increased production of IFN-γ,i t
is possible that the increased cytotoxicity seen with Daudi
is an indirect effect, mediated through IFN-γ. To address
Isotype
Control
anti-IFNγ
C
D
1
0
7
a
(
%
 
P
o
s
i
t
i
v
e
)
0
5
10
15
20
0
400
800
1200
C
y
t
o
t
o
x
i
c
i
t
y
(
L
U
3
0
/
1
0
7
c
e
l
l
s
)
a
b
IL-12 + IL-18
IL-12 + IL-18 + TL1A
0
5
10
15
20
I
F
N
-
γ
 
S
e
c
r
e
t
i
o
n
(
n
g
/
m
l
)
c
Fig. 4 TL1A enhancement of IL-12/IL-18-induced cytotoxicity to
Daudi cells is marked by increased surface expression of CD107a and
is not significantly affected by the presence of IFN-γ. Purified NK
were cultured for 72 h with IL-12 and IL-18 with or without TL1A
(20 ng/ml), and their cytolytic activity (a) was tested against Daudi
under IFN-γ blocking conditions in a FCC assay in which CD107a
expression (b) was concurrently assessed. Production of IFN during
the 2 h assay period was also monitored (c). Representative results for
two experiments are shown
536 J Clin Immunol (2010) 30:531–538this concern, we tested the lytic activity of purified NK
cells in the presence of IFN-γ blocking antibody in a flow
cytometric cytotoxicity assay [16]. This allowed us to
assess IFN-γ production during the 2-h cytotoxicity assay
and also simultaneously measure lysosomal-associated
membrane protein-1 (LAMP-1, CD107a), a marker associ-
ated with increased cytotoxic activity [1, 2]. As seen in
Fig. 4a and c, cytolytic activity was unchanged by the
blocking conditions for both IL-12/IL-18 and IL-12/IL18 +
TL1A despite a 5-fold reduction in the concentration of
IFN-γ. CD107a expression was increased with IL-12/IL-18
(data not shown), further increased with TL1A and was also
unaffected by IFN-γ blockade (Fig. 4b), supporting the
concept that TL1A directly enhances the cytolytic potential
of NK cells.
Discussion
Our results show that TL1A significantly enhances the
cytolytic activity of NK cells costimulated by IL-12/IL-18
against the NK resistant leukemic Daudi targets and to a
lesser degree against WiDr and SW837 epithelial tumor
cells. Although only a few target cell lines (K562, Daudi,
WiDr, and SW837) were tested for susceptibility to lysis by
PBMC or purified NK cells activated by IL-12/IL-18
without and with TL1A, the results suggest that TL1A
preferentially potentiates lytic activity of activated NK cells
against otherwise NK-resistant targets (Daudi, WiDr, and
SW837), while not increasingt h ea l r e a d ys u b s t a n t i a l
cytolytic activity against NK-sensitive targets (K562).
Whether the relative greater enhancement of the NK cell
lysis by the hematopoetic tumor cell Daudi compared to the
solid epithelial tumors suggests a more potent effect of
TL1A on this class of tumors will require further study.
Interestingly, TL1A resulted in a 2-fold increase in
cytotoxicity of non-NK cells, largely T cells, and thus, the
effect of TL1A on cytotoxicity is not limited to NK cells.
Since augmentation of cytotoxicity against NK-resistant
targets by TL1A is dependent on IL-12/IL-18, TL1A could
contribute to IL-12/IL-18-induced modulations of NK lytic
mechanisms and/or NK-target cell recognition and NK
activation. In this context, we have shown that TL1A does
increase the surface expression of LAMP-1 on NK cells
costimulated with IL-12/IL-18. LAMP-1 expression is
associated with both NK cytotoxicity and IFN-γ secretion
[1, 2] and may be related to induction of other factors
influential in NK killing. Cytokine stimulations such as IL-
2, IL-12, and IL-18 have also been shown to enhance
perforin binding to the target cell membrane [17], increase
the expression of the natural cytotoxicity receptor NKp44
[21], alter the NKG2D receptor activity [3, 7, 26, 27], and
override signals from the inhibitory Ly49G2 receptor [15,
22]. It remains to be seen if TL1A plays a role in any of
these mechanisms. Although IFN-γ has been shown to play
an important role in the modulation of key surface receptors
or ligands (e.g., MHC class I, Fas, and TRAIL), our results
show the IFN-γ levels produced with TL1A do not seem to
be involved in TL1A-induced cytotoxicity.
TL1A has been shown to play an important role in
modulating the adaptive immune response, both in Th1
(murine colitis [30]) and Th2 (allergic lung inflammation
[9]) disease models as well as a Th17-mediated autoim-
mune disease model [24], making the TL1A pathway an
attractive target for potential therapy. Our results suggest
that care should be taken such that immune surveillance of
hematopoietic tumors is not compromised with anti-TL1A
therapeutics.
Conclusions
We demonstrated that TL1A selectively enhances IL-12/IL-
18-induced NK cell cytotoxicity against Daudi cells and
other NK-resistant tumor targets, thereby potentiating the
cytolytic activity of activated NK cells independent of IFN-
γ. The signaling pathways involved in TL1A enhancement
of IL-12/IL-18-induced cytotoxicity and the mechanisms
underlying its preferential effect on NK cell-mediated lysis
of resistant targets deserve further studies and may
elucidate a possible role for TL1A in tumor surveillance
and therapy.
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